(DVA) DaVita HealthCare Partners - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US23918K1088
DVA: Dialysis, Labs, Research, Software, Care, Services, Management
DaVita Inc. (NYSE:DVA) is a leading provider of kidney dialysis services for patients with chronic kidney failure in the United States. The company operates a vast network of outpatient dialysis centers, offering a range of services including hemodialysis, peritoneal dialysis, and home-based dialysis care. Beyond its core dialysis operations, DaVita provides clinical laboratory services, disease management programs, and integrated care services for patients with end-stage renal disease (ESRD). Its comprehensive offerings extend to acute inpatient dialysis, physician services, and transplant software solutions.
DaVitas business model is heavily integrated, allowing it to manage the full spectrum of kidney care. The company partners with nephrologists and healthcare providers to deliver coordinated care, reducing hospitalizations and improving patient outcomes. Its scale and operational efficiency make it one of the largest dialysis providers in the U.S., with a significant market share. DaVita also engages in clinical research initiatives, contributing to advancements in kidney disease treatment and management.
From a financial perspective, DaVita Inc. operates with a market capitalization of approximately $14.5 billion, reflecting its established position in the healthcare services sector. The companys valuation metrics, such as a P/E ratio of 19.08 and a forward P/E of 15.29, indicate a premium valuation relative to its earnings. The P/S ratio of 1.15 highlights its revenue generation capabilities. These metrics are important for investors assessing the companys growth prospects and profitability in the dialysis and kidney care space.
Headquartered in Denver, Colorado, DaVita Inc. was founded in 1994 and has since grown into a critical player in the healthcare services industry. Its focus on patient care, operational excellence, and innovation positions it as a key participant in the evolving landscape of kidney disease management. For investors and fund managers, DaVita represents a significant entity in the healthcare sector, with a strong track record of delivering essential services to patients with chronic kidney failure.
Web URL: https://www.davita.com
Additional Sources for DVA Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
DVA Stock Overview
Market Cap in USD | 11,290m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 1995-10-31 |
DVA Stock Ratings
Growth 5y | 57.6% |
Fundamental | 62.6% |
Dividend | 0.0% |
Rel. Strength Industry | 4.55 |
Analysts | 3.1/5 |
Fair Price Momentum | 140.60 USD |
Fair Price DCF | 424.69 USD |
DVA Dividends
No Dividends PaidDVA Growth Ratios
Growth Correlation 3m | -26.8% |
Growth Correlation 12m | 72.5% |
Growth Correlation 5y | 46.9% |
CAGR 5y | 14.84% |
CAGR/Max DD 5y | 0.29 |
Sharpe Ratio 12m | 1.37 |
Alpha | -4.39 |
Beta | 0.87 |
Volatility | 37.64% |
Current Volume | 759.4k |
Average Volume 20d | 1210k |
As of March 15, 2025, the stock is trading at USD 143.45 with a total of 759,408 shares traded.
Over the past week, the price has changed by -2.43%, over one month by -8.87%, over three months by -4.74% and over the past year by +5.48%.
Yes, based on ValueRay Fundamental Analyses, DaVita HealthCare Partners (NYSE:DVA) is currently (March 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 62.58 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DVA as of March 2025 is 140.60. This means that DVA is currently overvalued and has a potential downside of -1.99%.
DaVita HealthCare Partners has received a consensus analysts rating of 3.10. Therefor, it is recommend to hold DVA.
- Strong Buy: 1
- Buy: 0
- Hold: 8
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, DVA DaVita HealthCare Partners will be worth about 151.9 in March 2026. The stock is currently trading at 143.45. This means that the stock has a potential upside of +5.86%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 163.3 | 13.8% |
Analysts Target Price | 161.6 | 12.6% |
ValueRay Target Price | 151.9 | 5.9% |